Physician profile
Sara B Eckrich
NPI 1174858187
$784.27
in general payments reported to CMS, 2019-2025
14 companies · $27.80 in 2025
The $27.80 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $205 · 2022: $163 · 2023: $77.29 · 2024: $312 · 2025: $27.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $417.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $180.26 | 2021-2025 | |
| Gilead Sciences, INC. | $158.87 | 2021-2024 | Epclusa |
| Pfizer INC. | $81.55 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $79.55 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.65 | 2024 | Relistor |
| Scilex Pharmaceuticals INC. | $34.00 | 2024 | |
| Orexo US, INC. | $29.23 | 2022-2023 | Zubsolv |
| Vanda Pharmaceuticals INC. | $27.67 | 2022 | |
| Corium, LLC | $24.13 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.04 | 2021 | |
| Alkermes, INC. | $23.59 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.55 | 2022 | |
| Oxford Immunotec USA INC | $18.55 | 2021 | |
| Braeburn INC. | $13.63 | 2024 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Eckrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.